Steven H Stein - Net Worth and Insider Trading
Steven H Stein Net Worth
The estimated net worth of Steven H Stein is at least $8 Million dollars as of 2023-03-28. Steven H Stein is the EVP & Chief Medical Officer of Incyte Corp and owns about 109,021 shares of Incyte Corp (INCY) stock worth over $8 Million. Details can be seen in Steven H Stein's Latest Holdings Summary section.
Transaction Summary of Steven H Stein
Steven H Stein Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Steven H Stein owns 3 companies in total, including Incyte Corp (INCY) , Kura Oncology Inc (KURA) , and Theseus Pharmaceuticals Inc (THRX) .
Click here to see the complete history of Steven H Stein’s form 4 insider trades.
Insider Ownership Summary of Steven H Stein
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INCY | Incyte Corp | 2016-05-02 | EVP & Chief Medical Officer |
| KURA | Kura Oncology Inc | 2017-01-03 | director |
| THRX | Theseus Pharmaceuticals Inc | 2022-10-17 | director |
Steven H Stein Latest Holdings Summary
Steven H Stein currently owns a total of 1 stock. Steven H Stein owns 109,021 shares of Incyte Corp (INCY) as of January 4, 2023, with a value of $8 Million.
Latest Holdings of Steven H Stein
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| INCY | Incyte Corp | 2023-01-04 | 109,021 | 70.31 | 7,665,267 |
Holding Weightings of Steven H Stein
Steven H Stein Form 4 Trading Tracker
According to the SEC Form 4 filings, Steven H Stein has made a total of 6 transactions in Incyte Corp (INCY) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Incyte Corp is the sale of 28,399 shares on January 4, 2023, which brought Steven H Stein around $2 Million.
Insider Trading History of Steven H Stein
- 1
Steven H Stein Trading Performance
Steven H Stein Ownership Network
Ownership Network List of Steven H Stein
Ownership Network Relation of Steven H Stein
Steven H Stein Owned Company Details
What does Incyte Corp do?
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Who are the key executives at Incyte Corp?
Steven H Stein is the EVP & Chief Medical Officer of Incyte Corp. Other key executives at Incyte Corp include Principal Accounting Officer Thomas Tray , EVP & Head of Tech. Operations Michael James Morrissey , and EVP & General Manager & Europe Jonathan Elliott Dickinson .
Incyte Corp (INCY) Insider Trades Summary
Over the past 18 months, Steven H Stein made 1 insider transaction in Incyte Corp (INCY) with a net sale of 28,399. Other recent insider transactions involving Incyte Corp (INCY) include a net purchase of 2,510,403 shares made by Baker Bros. Advisors Lp , a net sale of 30,111 shares made by Vijay K Iyengar , and a net sale of 46,866 shares made by Barry P Flannelly .
In summary, during the past 3 months, insiders sold 97,842 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 97,842 shares. During the past 18 months, 209,240 shares of Incyte Corp (INCY) were sold and 2,510,403 shares were bought by its insiders, resulting in a net purchase of 2,301,163 shares.
Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Incyte Corp Insider Transactions
Steven H Stein Mailing Address
Above is the net worth, insider trading, and ownership report for Steven H Stein. You might contact Steven H Stein via mailing address: 1801 Augustine Cut-off, Wilmington De 19803.
